Wells Fargo & Company Cuts Disc Medicine (NASDAQ:IRON) Price Target to $78.00

Disc Medicine (NASDAQ:IRON) had its target price cut by Wells Fargo & Company from $109.00 to $78.00 in a research report released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also recently issued reports about the stock. BMO Capital Markets dropped their target price on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Tuesday. TD Cowen reissued a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Morgan Stanley reissued an “overweight” rating and issued a $120.00 target price on shares of Disc Medicine in a research report on Thursday, January 8th. Finally, Wedbush lowered their target price on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research note on Tuesday. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.82.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $63.35 on Tuesday. The business has a 50 day moving average of $77.24 and a 200 day moving average of $75.12. Disc Medicine has a 52 week low of $30.82 and a 52 week high of $99.50. The company has a market cap of $2.39 billion, a PE ratio of -11.84 and a beta of 0.88. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05.

Insider Transactions at Disc Medicine

In related news, insider William Jacob Savage sold 3,256 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $204,672.16. Following the transaction, the insider owned 92,589 shares in the company, valued at $5,820,144.54. The trade was a 3.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jean M. Franchi sold 7,081 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $65.47, for a total transaction of $463,593.07. Following the completion of the transaction, the chief financial officer owned 71,343 shares in the company, valued at approximately $4,670,826.21. This represents a 9.03% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 284,761 shares of company stock valued at $24,913,484. 3.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Hedge funds have recently added to or reduced their stakes in the stock. ANTIPODES PARTNERS Ltd bought a new stake in shares of Disc Medicine in the fourth quarter worth $33,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Disc Medicine during the 3rd quarter valued at about $38,000. CWM LLC grew its stake in shares of Disc Medicine by 213.5% during the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares during the period. KBC Group NV purchased a new stake in shares of Disc Medicine during the 4th quarter valued at about $80,000. Finally, Avanza Fonder AB lifted its stake in shares of Disc Medicine by 54.0% in the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after purchasing an additional 585 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Management said it will pursue a traditional U.S. approval pathway for lead drug bitopertin after the FDA declined a fast‑track route, giving investors a clearer regulatory path rather than abandoning the program. Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod
• Positive Sentiment: Several sell‑side firms (Cantor Fitzgerald, Stifel) have maintained constructive ratings (buy/overweight) even as some trimmed targets, which can support institutional interest and limit downside. Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald Stifel Nicolaus Sticks to Its Buy Rating for Disc Medicine (IRON)
• Neutral Sentiment: Market commentary and valuation checks are active as investors parse the FDA Complete Response Letter and implications for timing — some outlets ran valuation pieces and transcripts of the company investor call. Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin Program
• Neutral Sentiment: Reported short‑interest prints are noisy/insignificant in the latest data, so today’s move looks driven largely by event‑driven trading and position rebalancing rather than a classic short‑squeeze dynamic.
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Disc Medicine, introducing potential litigation risk and adding headline pressure that can deter buyers. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
• Negative Sentiment: Multiple insiders sold sizable blocks this week (CEO, CFO, COO and others), which investors often interpret as negative signal about near‑term outlook even though insiders still hold meaningful equity. John Quisel Sells 13,264 Shares of Disc Medicine (NASDAQ:IRON) Stock
• Negative Sentiment: HC Wainwright and other firms cut near‑ and long‑term EPS forecasts and several shops trimmed price targets, lowering the near‑term valuation baseline until regulatory clarity and data timelines are resolved.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.